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Abstract: Objectives: Approximately up to 40% of patients with rheumatoid arthritis (RA) fail to respond to tumor necro-
sis factor (TNF) inhibitors, lose response over time or are unable to tolerate treatment. 
Materials and Methodology: We report two female patients suffering from active, refractory rheumatoid arthritis despite 
TNF blocking agents who have been treated with rituximab added to ongoing therapy with etanercept. 
Results: Combination therapy was tolerated without any acute side effects. Both patients improved with a significant, long 
lasting reduction of disease activity (DAS28, CRP). Evaluation of the immunological parameters showed the expected B-
cell depletion and a transient reduction of immunoglobulin-levels. One patient developed four serious infections requiring 
antibiotic treatment (1 pneumonia, 3 exacerbations of her pre-existing chronic bronchitis) within follow up of 45 months. 
Conclusion: Combination therapy of rituximab and etanercept lead to a significant improvement of clinical disease activ-
ity and inflammatory parameters in two RA patients refractory to anti-TNF treatment. 
Keywords: Rheumatoid arthritis, rituximab, etanercept, TNF failure. 
INTRODUCTION 
  Rheumatoid arthritis (RA) represents a chronic inflam-
matory disease leading to progressive joint destruction, im-
mobilisation and increased mortality. RA is treated with 
DMARDs (disease modifying anti-rheumatic drugs) alone or 
in combination with glucocorticoids and/or so called bi-
ologicals, e.g. TNFalpha-antagonists. The introduction of 
TNFalpha blockers undoubtedly has revolutionized treat-
ment of RA. Nevertheless, up to 40% of by this means 
treated patients do not respond adequately, lose response 
over time or are unable to tolerate treatment requiring alter-
native therapeutic options. These include a different TNF 
inhibitor, the T-cell co-stimulation modulator abatacept, or 
the B-cell depleting rituximab [1, 2]. Rituximab, a mono-
clonal antibody that selectively targets CD20-positive B 
cells, in combination with methotrexate is effective and well-
tolerated in the treatment of RA patients who have had an 
inadequate response to one or more TNF inhibitors [3, 4]. It 
has been discussed recently that efficacy of TNF blocking 
agents may be restored by combination with rituximab. In 
general, combination therapy is a well proven concept in RA 
treatment e.g. combination of conventional DMARDs or 
methotrexate with TNF blockers, rituximab or abatacept. 
There are only very few experiences regarding the combina-
tion of biologicals. Combination of anti cytokine principles  
seems to increase susceptibility to infections. Combination 
of cytokine and cell targeted principles may prove to be 
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advantageous. We report two female patients in whom due to 
numerous ineffective therapies combination therapy of etan-
ercept and rituximab was applied. 
RESULTS 
Patient 1 
  62 year old female was diagnosed seropositive RA in 
1987. At this time, radiological erosive joint damage was 
already present. Therapy with oral and later parenteral gold 
was provided for more than five years with very little clinical 
benefit. Following this, the patient was successfully treated 
with methotrexate for four years. MTX had to be terminated 
in 1999 due to MTX pneumonitis and leflunomide was 
started. Because of high disease activity and radiological 
progress (also with involvement of the atlantodental joint) 
treatment with etanercept was initiated in February 2000 
with initially good response. At the end of 2001 an increase 
in RA activity could be observed and rituximab was applied 
within the framework of a local pilot study in the use of 
rituximab for RA February 2002. Altogether 4 infusions of 
rituximab were administered at weekly intervals in dosages 
of 375 mg/m
2 under premedication with paracetamol (1000 
mg) and clemastin (1 mg) without significant acute side 
effects. The preceding antirheumatic therapy with etanercept 
25 mg twice weekly, leflunomide 20 mg and prednisolone 
2.5 mg daily was continued. After rituximab therapy a meas-
urable decrease of disease activity (decline of DAS28 from 
5.7 to 4.4 after three months) was observed lasting up to 
2007 with a DAS28 < 3 (Table 1). In addition the radiologi-
cal assessment showed no progression between 2002 and 
2006. 25 months after rituximab therapy and 13 months after 
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and treated successfully with antibiotics. In november 2004 
(34 months after rituximab), october 2005 (45 months after 
rituximab) and january 2006 (48 months after rituximab), 
acute bronchitides as infective exacerbations of the patients 
known chronic bronchitis occurred and were successfully 
treated. No opportunistic infection occurred at all. The pa-
tient was retreated with rituximab in 2008 due to increasing 
disease activity with radiological progress compared to 2006. 
Etanercept was stopped. Five months after retreatment with 
rituximab clinical remission could be documented (DAS28 
1.9). 
Patient 2 
  A 33 year old female patient was diagnosed a seroposi-
tive RA in 1986. Comorbidities in this patient include a 
successfully treated mammary carcinoma in 1990, osteopo-
rosis and hypercholesteremia. RA treatment so far included 
Chloroquin (thrombocytopenia), gold parenterally (thrombo-
cytopenia), sulfasalazine (ineffectiveness), methotrexate 
(mucositis) and leflunomide (ineffectiveness). Etanercept as 
monotherapy was started in 2000 (2x25 mg/week) with 
clinical improvement and only minimal residual disease 
activity. Due to increasing disease activity with destructive 
arthritis in the left elbow and right wrist joints treatment with 
rituximab within the framework of a monocentric pilot study 
was applied in 5/2002 (treatment protocol see above) while 
therapy with etanercept was continued. The patient improved 
significantly and the general clinical activity parameters 
decreased (Table 1). Only a single synovialitis in the left 
elbow joint persisted, so that local therapy with glucocorti-
coids as well as consecutive synovectomy of the left elbow 
joint were done in February 2004. Under continued etaner-
cept treatment, the patient stayed in remission without radio-
logical progress between 2002 and 2005. Relevant infectious 
complications or opportunistic infections did not occur at 
any time. Radiological assessment in 2008 revealed a slight  
progress of erosions in two MTP joints without any change 
for the hands while clinical remission (DAS28 1.8) persisted 
under etanercept monotherapy. 
Immunological Parameters 
  In both patients sufficient IgG antibody titers against 
tetanus, mumps, measles, rubella, Epstein-Barr, cytomegalo 
and herpes virus 1 and 2 prior to commencing rituximab 
therapy could be detected (data not shown). These antibody 
titers did not show a falling tendency after rituximab therapy 
(45 months observation period). Rheumatoid factor (RF) 
dropped significantly in both patients. In patient 1, minimal 
values of 20% compared to baseline were measured after 15 
months. In patient 2, minimal values of 59% were reached 
after 9 months (Table 1). While in patient 1 RF stayed low-
ered for even 45 months, the rheumatoid factor increased to 
initial values in patient 2 in the course of time. 
  In patient 1 immunoglobulins G, A and M levels (Table 
1) showed only a transitory drop of IgG levels below the 
normal range 6 months after RTX therapy. IgM and IgA 
dropped slightly, but remained within the normal range. 
Patient 2 showed no relevant variations regarding IgG and 
IgA levels. 
  After therapy a complete depletion of CD19
+ B cells was 
observed in both patients (Fig. 1). This lasted for eight 
months in patient 1, and 10 months in patient 2. Patient 1 
already showed a complete numeric regeneration of CD19
+ 
B-cells within 12 months after rituximab. In patient 2, the 
starting level of CD19
+ B-cells was reached after 16 months. 
During the regeneration phase, the CD27-IgD
+ naive B cells 
increased continuously (data not shown) and represented the 
numerically dominant population in the peripheral B-cell 
pool two years after rituximab. In contrast, CD19
+CD27
+ 
memory B cells stayed suppressed (Fig. 1). B cell regenera-
tion was not accompanied by an increase in disease activity. 
 
Table 1.  Clinical and Laboratory Parameters After One Cycle of Rituximab (RTX) with Ongoing Etanercept Treatment: DAS28, 
IgG, IgA, IgM and Rheumatoid Factor (RF); Values Below the Normal Range are Grey (Values in % Compared to the 
Starting Level) 
 
Patient 1 
Months after RTX  0 3  6  9  15  45 
DAS28  5,7 4,4    4,4  4,8  3,5  2,13 
IgG (690-1600 mg/dl)  884 835  (94)  671 (76)  690 (78)  909 (103)  877 (99) 
IgA (70-370 mg/dl)  283  250 (88)  197 (70)  210 (74)  244 (86)  301 (106) 
IgM (40-240 mg/dl)  138  104 (75)  72 (52)  87 (63)  76 (55)  91 (66) 
RF (U/l)  267  139 (52)  127 (48)  62 (23)  54 (20)  123 (46) 
Patient 2 
Months after RTX  0 3  6  9  12  45 
DAS28  5 3,9  3,3  2,58  2,44  2,78 
IgG (690-1600 mg/dl)  1100   1180 (107)  1100 (100)  1100 (100)  1200 (109)  1345 (122) 
IgA (70-370 mg/dl)  228  260 (114)  246 (108)  261 (114)  300 (130)  309 (135) 
IgM (40-240 mg/dl)  66  59 (90)  49 (79)  59 (90)  53 (80)  48 (76) 
RF (U/l)  174  131 (75)  107 (61)  103 (59)  136 (78)  172 (99) Combination Therapy with Rituximab and Etanercept in RA  The Open Rheumatology Journal, 2009, Volume 3    11 
 
DISCUSSION 
  The efficacy of TNF-alpha blockers for rheumatoid ar-
thritis therapy is very well proven in clinical studies and 
daily praxis. Nevertheless, approximately 40% of patients 
with RA treated with TNF inhibitors do not respond well or 
fail to respond in the course of time. Meanwhile there are 
some new biological agents having been approved for TNF 
refractory patients like abatacept or rituximab. Only a limited 
number of patients treated by this means showed a clinically 
relevant improvement of disease activity in the situation of 
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Fig. (1). Reconstitution of B cells after one cycle of rituximab (RTX) with ongoing etanercept treatment. 12    The Open Rheumatology Journal, 2009, Volume 3  Feuchtenberger et al. 
TNF failure like ACR50 and 70 response [4-7]. Combination 
therapy therefore may be an option. In general combination 
therapy is an important and well proven treatment concept in 
RA and was validated for various substances in clinical stud-
ies e.g. combination of conventional DMARDs [8] or com-
bination of methotrexate with TNF-alpha blockers, abatacept 
or rituximab. On the other hand, there are also data on com-
bination of TNF blocking agents with the costimulation 
blocker abatacept or anakinra leading to a significant in-
creased infection rate [7, 9]. Therefore this combination 
currently is not recommended. 
  Combination of a cytokine blocking agent like etanercept 
and a cell targeted agent like rituximab may have advantages 
in that respect. The combination of the B-cell depleting an-
tiCD20 antibody rituximab and etanercept in our two pa-
tients showed a clinically relevant improvement measured by 
DAS28, CRP and radiological assessment leading to low 
disease activity in both patients up to 45 months after initia-
tion of combination therapy. Our data so far are in congru-
ence with data for six patients treated with etanercept and 
rituximab which have been recently presented (abstract) at 
the EULAR 2008. A significant reduction in disease activity 
measured by DAS28 and CRP six months after combination 
of rituximab and etanercept in these six patients being refrac-
tory to etanercept alone was shown, suggesting the superior-
ity of the combination therapy with rituximab [10]. No sig-
nificant increase in infections and no opportunistic or fatal 
infections could be observed. Of course, due to the lack of 
controlled trials, from data available up to now it cannot be 
proved combination of etanercept and rituximab leading to a 
synergistic effect in terms of efficacy. Response observed so 
far could also be attributed to the shift to rituximab per se. 
  Meanwhile there are also some data available on the 
safety aspect of a biological combination therapy with ri-
tuximab and other biological agents presented at the ACR 
2008 (abstract). 185 patients within a safety follow up pro-
gramme of patients who have been treated at least once with 
rituximab within an international trial programme were al-
lowed to be treated with another biological agent in the fol-
lowing (n = 150 TNF blocking agents, n = 25 abatacept, 
anakinra or natalizumab) [11]. There was no significant 
difference in the rate of serious infections after initiation of 
the second biologic agent (5.49/100pty) compared to the 
observational period before (6.99/100pty). Serious infections 
were defined as infections that required intravenous antibiot-
ics or met the regulatory criteria for a serious adverse event 
like hospitalization, prolongation of an existing hospitaliza-
tion or immediately life-threatening infections. The median 
period under review was 186 patient years before and 182 
patient years after initiation of the second biological agent. 
The time of onset (median 7 months after initiation of the 
second biological agent) or the sort of infections under com-
bination therapy did not show specific characteristics but 
was more or less typical for RA patients in general (urinary 
tract infections, pneumonia, bronchitis or gastroenteritis). 
The infectious complications in our case report (patient 1) 
were also typical for the patient who was at risk due to her 
pre-existing chronic pulmonary disease. The infectious com-
plications are unlikely linked to combination therapy of 
rituximab and etanercept since the onset of infection took 
place after B cell regeneration was completed and IgG levels 
have returned to the normal range. Nevertheless, patients 
with comorbidities like COPD probably may need special 
surveillance within such concepts. 
  Both patients showed a significant drop in IgM levels up 
to 48% (patient 1) and 24% (patient 2), respectively, com-
pared to baseline levels without values below the normal 
range. Such changes are known from larger patient collec-
tives after rituximab therapy and are evidently not linked to 
heightened risk of infection [3]. In patient 1, there was a 
transient reduction in IgG by more than 20%, which barely 
lay below the normal range. At the onset of pneumonia, IgG 
levels have had normalised for several months. Due to the 
limited time of IgG reduction as well as the very slight IgM 
reduction months before the infections occurred, a direct 
relation to the described respiratory tract infections initially 
appears unlikely. Additionally B cell count and even overall 
memory B cell count has had normalized for more than 20 
months. Regeneration of B-cells in our two patients was 
mainly carried out by CD27-IgD naive B while 
CD19
+CD27
+ memory B cells stayed suppressed. The im-
munological parameters in our patients with rituximab and 
etanercept combination therapy did not differ from the data 
published for rituximab/MTX therapy so far [12]. 
CONCLUSION 
  Our case report shows that the combination of rituximab 
and etanercept was feasible and lead to a clinically relevant 
and long lasting improvement in disease activity in two pa-
tients with RA refractory to anti-TNF treatment alone. No 
acute side effects or opportunistic infections could be de-
tected. The combination of rituximab and etanercept there-
fore maybe a therapeutical option for patients with TNF 
failure. To address this, there is an obvious need for further 
studies to secure the casuistically observed good efficacy and 
compatibility of the TNF blocking agent etanercept with 
rituximab. 
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